References
- Gudjonsson JE, Elder JT. Psoriasis: epidemiology. Clin Dermatol. 2007;25:535–546.
- Di Lernia V, Goldust M. An overview of the efficacy and safety of systemic treatments for psoriasis in the elderly. Expert Opin Biol Ther. 2018;18:897–903.
- Napolitano M, Balato N, Ayala F, et al. Psoriasis in elderly and non-elderly population: clinical and molecular features. G Ital di dermatologia e Venereol organo Uff Soc Ital di dermatologia e Sifilogr. 2016;151:587–595.
- Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years: is elderly-onset psoriasis a distinct subtype? Int J Dermatol. 2012;51:53–58.
- Grozdev IS, Van Voorhees AS, Gottlieb AB, et al. Psoriasis in the elderly: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2011;65:537–545.
- Balato N, Patruno C, Napolitano M, et al. Managing moderate-to-severe psoriasis in the elderly. Drugs Aging. 2014;31:233–238.
- Sampogna F, Chren MM, Melchi CF, et al. Age, gender, quality of life and psychological distress in patients hospitalized with psoriasis. Br J Dermatol. 2006;154:325–331.
- Maul J-T, Navarini AA, Sommer R, et al. Gender and age significantly determine patient needs and treatment goals in psoriasis - a lesson for practice. J Eur Acad Dermatol Venereol. 2019;33:700–708.
- Sampogna F, Tabolli S, Mastroeni S, et al. Quality of life impairment and psychological distress in elderly patients with psoriasis. Dermatology. 2007;215:341–347.
- Yosipovitch G, Tang MBY. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. Drugs Aging. 2002;19:847–863.
- Geale K, Henriksson M, Schmitt-Egenolf M. Evaluating equality in psoriasis healthcare: a cohort study of the impact of age on prescription of biologics. Br J Dermatol. 2016;174:579–587.
- Migliore A, Bizzi E, Laganà B, et al. The safety of anti-TNF agents in the elderly. Int J Immunopathol Pharmacol. 2009;22:415–426.
- Esposito M, Giunta A, Mazzotta A, et al. Efficacy and safety of subcutaneous anti-tumor necrosis factor-alpha agents, etanercept and adalimumab, in elderly patients affected by psoriasis and psoriatic arthritis: an observational long-term study. Dermatology. 2012;225:312–319.
- Borren NZ, Ananthakrishnan AN. Safety of biologic therapy in older patients with immune-mediated diseases: a systematic review and meta-analysis. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2019;17(9):1736.e4–1743.e4.
- Saraceno R, Saggini A, Pietroleonardo L, et al. Infliximab in the treatment of plaque type psoriasis. Clin Cosmet Investig Dermatol. 2009;2:27–37.
- Chiricozzi A, Pavlidis A, Dattola A, et al. Efficacy and safety of infliximab in psoriatic patients over the age of 65. Expert Opin Drug Saf. 2016;15:1459–1462.
- ENBREL. Etanercept (ENBREL) - Prescribing information; 1998. cited 2022 Feb 11. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103795s5503lbl.pdf.
- Campanati A, Diotallevi F, Martina E, et al. Safety update of etanercept treatment for moderate to severe plaque psoriasis. Expert Opin Drug Saf. 2020;19:439–448.
- Militello G, Xia A, Stevens SR, et al. Etanercept for the treatment of psoriasis in the elderly. J Am Acad Dermatol. 2006;55:517–519.
- Wu JJ, Valdecantos WC. Adalimumab in chronic plaque psoriasis: a clinical guide. J Drugs Dermatol. 2017;16:779–790.
- Menter A, Gordon KB, Leonardi CL, et al. Efficacy and safety of adalimumab across subgroups of patients with moderate to severe psoriasis. J Am Acad Dermatol. 2010;63:448–456.
- Chiricozzi A, Zangrilli A, Bavetta M, et al. Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study. J Eur Acad Dermatol Venereol. 2017;31:304–311.
- Lee A, Scott LJ. Certolizumab pegol: a review in moderate to severe plaque psoriasis. BioDrugs. 2020;34:235–244.
- CIMZIA. Certolizumab pegol (CIMZIA) - Prescribing information; 2021. cited 2022 Mar 11. Available from: https://www.ema.europa.eu/en/documents/product-information/cimzia-epar-product-information_en.pdf.
- SIMPONI. Golimumab (SIMPONI) - Prescribing information. cited 2022 Mar 11. Available from: https://www.ema.europa.eu/en/documents/product-information/simponi-epar-product-information_en.pdf.
- STELARA. Ustekinumab (STELARA) - Prescribing information. cited 2022 Feb 11. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761044lbl.pdf.
- Megna M, Napolitano M, Balato N, et al. Efficacy and safety of ustekinumab in a group of 22 elderly patients with psoriasis over a 2-year period. Clin. Exp 2016; 41(5):564–566
- Hayashi M, Umezawa Y, Fukuchi O, et al. Efficacy and safety of ustekinumab treatment in elderly patients with psoriasis. J Dermatol. 2014;41:974–980.
- Momose M, Asahina A, Hayashi M, et al. Biologic treatments for elderly patients with psoriasis. J Dermatol. 2017;44:1020–1023.
- Shary N, Kalb RE. Optimizing the treatment of moderate ‑ to ‑ severe psoriasis in older adults. Drugs Aging. 2020;37:715–723. Available from.
- Phan C, Beneton N, Delaunay J, et al. Effectiveness and safety of anti-interleukin-17 therapies in elderly patients with psoriasis. Acta Derm Venereol. 2020;100:adv00316.
- COSENTIX. Secukinumab (COSENTIX) - Prescribing information. cited 2022 Jan 21. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125504s043lbl.pdf.
- Körber A, Papavassilis C, Bhosekar V, et al. Efficacy and safety of secukinumab in elderly subjects with moderate to severe plaque psoriasis: a pooled analysis of phase III studies. Drugs Aging. 2018;35:135–144.
- Wu JJ, Merola JF, Feldman SR, et al. treatment of psoriasis with secukinumab in challenging patient scenarios: a review of the available evidence. Dermatol Ther. 2020;10:351–364.
- Megna M, Camela E, Cinelli E, et al. Real-life efficacy and safety of secukinumab in elderly patients with psoriasis over a 2-year period. Clin Exp Dermatol. 2020;45:848–852.
- Sandhu VK, Ighani A, Fleming P, et al. Biologic treatment in elderly patients with psoriasis: a systematic review. J Cutan Med Surg. 2020;24:174–186.
- Di Caprio R, Caiazzo G, Cacciapuoti S, et al. Safety concerns with current treatments for psoriasis in the elderly. Expert Opin Drug Saf. 2020;19:523–531.
- Ricceri F, Pescitelli L, Lazzeri L, et al. First case of secukinumab successful therapy in a very elderly psoriatic patient. Dermatol Ther. 2018; 31: e12668.
- Bakirtzi K, Sotiriou E, Papadimitriou I, et al. Elderly patients with psoriasis: long-term efficacy and safety of modern treatments. J Dermatolog Treat 2020 1–4 doi:10.1080/09546634.2020.1809623
- Kostović K, Žužul K, Čeović R, et al. Psoriasis in the mature patient: therapeutic approach in the era of biologics. Clin Dermatol. 2018;36:222–230.
- Di Lernia V, Bombonato C, Motolese A. COVID-19 in an elderly patient treated with secukinumab. Dermatol Ther. 2020: e13580
- TALTZ. Ixekizumab (TALTZ) - Prescribing information. cited 2022 Jan 22. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125521s014lbl.pdf.
- Megna M, Cinelli E, Balato A, et al. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period. J Eur Acad Dermatol Venereol Engl 2020; 34(3):e152–e153
- Gallo L, Ruggiero A, Fabbrocini G, et al. A case of severe psoriasis in a 84-year-old women successfully treated with ixekizumab. Dermatol Ther. 2020;33(3):e13299
- SILIQ. Brodalumab (SILIQ) Prescribing information. cited 2022 Jan 22. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761032lbl.pdf.
- Lebwohl M, Yamauchi P, Wu JJ, et al. Brodalumab in patients with psoriasis ages < 65 and 65 years: 120-week findings from two phase 3 studies. J Am Acad Dermatol. 2019;81:AB176.
- Lebwohl M, Menter A, Yamauchi P, et al. Brodalumab in patients with psoriasis ages <65 and 65 years: 120-week findings from two phase 3 studies. J Am Acad Dermatol. 2019;81:AB176.
- TREMFYA. Guselkumab (TREMFYA) Prescribing information. cited 2022 Jan 23. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/761061s007lbl.pdf.
- SKYRIZI. Risankizumab (SKYRIZI) Prescribing information. cited 2022 Jan 23. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761105s000lbl.pdf.
- ILUMYA. Tildrakizumab (ILUMYA) Prescribing information. cited 2022 Jan 23. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/761067s000lbl.pdf.
- Ruggiero A, Fabbrocini G, Cinelli E, et al. Anti-interleukin-23 for psoriasis in elderly patients: guselkumab, risankizumab and tildrakizumab in real-world practice. Clin Exp Dermatol. 2021;47:561–567.
- Crowley JJ, Warren RB, Cather JC. Safety of selective IL-23p19 inhibitors for the treatment of psoriasis. J Eur Acad Dermatol Venereol. 2019;33:1676–1684.
- Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392:650–661.
- Reich K, Papp KA, Blauvelt A, et al. Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials. Lancet. 2017;390:276–288.
- Ricceri F, Bardazzi F, Chiricozzi A, et al. Elderly psoriatic patients under biological therapies: an Italian experience. J Eur Acad Dermatol Venereol. 2019;33:143–146.
- Piaserico S, Conti A, Lo Console F, et al. Efficacy and safety of systemic treatments for psoriasis in elderly patients. Acta Derm Venereol. 2014;94:293–297.
- Tseng I-L, Yang -C-C, Lai E-C-C, et al. Psoriasis in the geriatric population: a retrospective study in Asians. J Dermatol. 2021;48:818–824.
- Wong JW, Koo JYM. The safety of systemic treatments that can be used for geriatric psoriasis patients: a review. Dermatol Res Pract. 2012;2012:367475.
- Padda IS, Bhatt R, Parmar M. Apremilast. Treasure Island (FL); 2022.
- OTEZLA. Apremilast (OTEZLA) prescribing information; 2017. cited 2022 Jan 14. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/205437s006lbl.pdf.
- OTEZLA. Apremilast (OTEZLA) - Prescribing information; 2021. cited Feb, 2022. Available from: https://www.ema.europa.eu/en/documents/product-information/otezla-epar-product-information_en.pdf.
- Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a phase III, randomized, controlled trial (Efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37–49.
- Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387–1399.
- Cline A, Cardwell LA, Feldman SR. Advances in treating psoriasis in the elderly with small molecule inhibitors. Expert Opin Pharmacother. 2017;18:1965–1973. Available from.
- Nast A, Spuls PI, van der Kraaij G, et al. European S3-Guideline on the systemic treatment of psoriasis vulgaris - update apremilast and secukinumab - EDF in cooperation with EADV and IPC. J Eur Acad Dermatol Venereol. 2017;31:1951–1963.
- Phan C, Beneton N, Delaunay J, et al. Real ‑ world effectiveness and safety of apremilast in older patients with psoriasis. Drugs Aging. 2020; 37: 657–663.
- Megna M, Fabbrocini G, Camela ECE. Apremilast efficacy and safety in elderly psoriasis patients over a 48-week period. J Eur Acad Dermatol Venereol. 2020;34:e705–e707.
- Chang BY, Zhao F, He X, et al. JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol. 2009;183:2183–2192.
- Yiu ZZN, Warren RB. Novel oral therapies for psoriasis and psoriatic arthritis. Am J Clin Dermatol. 2016;17:191–200.
- Berekmeri A, Mahmood F, Wittmann M, et al. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018;14:719–730.
- Bachelez H, van de Kerkhof PCM, Strohal R, et al. Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial. Lancet. 2015;386:552–561.
- Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173:949–961.
- Winthrop KL, Lebwohl M, Cohen AD, et al. Herpes zoster in psoriasis patients treated with tofacitinib. J Am Acad Dermatol. 2017;77:302–309.
- Fridman JS, Scherle PA, Collins R, et al. Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation. J Invest Dermatol. 2011;131:1838–1844.
- Papp KA, Menter MA, Raman M, et al. A randomized phase 2b trial of baricitinib, an oral Janus kinase (JAK) 1/JAK2 inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2016;174:1266–1276.
- Papp K, Pariser D, Catlin M, et al. A phase 2a randomized, double-blind, placebo-controlled, sequential dose-escalation study to evaluate the efficacy and safety of ASP015K, a novel Janus kinase inhibitor, in patients with moderate-to-severe psoriasis. Br J Dermatol. 2015;173:767–776.
- Medina C, Carretero G, Ferrandiz C, et al. Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry. J Eur Acad Dermatol Venereol. 2015;29:858–864.
- Garber C, Plotnikova N, Au S, et al. Biologic and conventional systemic therapies show similar safety and efficacy in elderly and adult patients with moderate to severe psoriasis. J Drugs Dermatol. 2015;14:846–852.
- Osuna CG, García SR, Martín JC, et al. Use of biological treatments in elderly patients with skin psoriasis in the real world. Life. 2021;11. doi:10.3390/life11121348.